Our first implementation brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with … Read More
Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform
Gene therapies delivered through a single administration have revolutionized treatment possibilities for many patients living with serious or fatal conditions such as spinal muscular atrophy, hemophilia, and sickle cell disease. … Read More
Managing the Challenges of Paying for Gene Therapy: New ICER / NEWDIGS whitepaper
ICER and NEWDIGS Release White Paper Analyzing the Challenges and Potential Policy Options for Paying for Gene Therapies — Paper outlines policy reforms and market actions to support innovation and … Read More
Better Outcomes Tracking: A First Step In Improving Access To New Treatments
New article in Health Affairs Forefront Transformative new pharmaceutical treatments hold the promise of changing patients’ lives by slowing and curing disease, improving well-being, and advancing quality of life. Yet, … Read More
Better Outcomes Tracking: A First Step In Improving Access To New Treatments
New article in Health Affairs Forefront Transformative new pharmaceutical treatments hold the promise of changing patients’ lives by slowing and curing disease, improving well-being, and advancing quality of life. Yet, … Read More
Emerging market solutions for financing and reimbursement of gene therapies for sickle cell disease: Why do payment innovation?
The FDA has approved two cell and gene therapies for sickle cell disease, marking a significant development for the largest population condition to date. However, the high treatment costs, … Read More
NEWDIGS welcomes Dr. Sharon Phares as new Associate Director for Research
NEWDIGS at Tufts Medical Center is excited to announce that Sharon Phares, PhD, MPH, has joined the team as our Associate Director for Research, Center for Biomedical System Design (CBSD), Tufts Medicine earlier this … Read More
Ask PAM: “How many?”
Individual Indication Workbook in actionHow many treatment-eligible people are in my population?The Pipeline Analysis and Modeling (PAM) in the NEWDIGS Paying for Cures Toolkit maintaints a unique, detailed, indication-by-indication analysis … Read More
Analyzing 340B and ASP interactions: Do Federal program rules disincentivize the use of VBCs, despite Medicaid Best Price reform?
This paper describes the interactions among Medicaid Best Price rebate calculations and those for 340B Ceiling Prices and Average Sales Prices which can create disincentives for providers and therapy developers … Read More
Orphan cell and gene therapies more likely to reach approval than larger drug pipeline: study
Our new report shows that cell and gene therapies for orphan diseases and hematological cancers are two to 3.5 times more likely to be successful than other types of treatments … Read More